This study evaluates the safety and efficacy simultaneous, trans-conjunctival, 25-Gauge vitrectomy and phacoemulsification with intraocular lens implant in patients with metamorphopsia and visual impairment due to idiopathic epiretinal membrane and cataract. All 30 patients recruited underwent complete ocular examination, visual acuity measurement with ETDRS, metamorphopsia assessment with M-Charts and Metamorphometry® and foveal thickness evaluation by sd-OCT preoperatively, at 30, 90, 180 days postoperatively.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Metamorphopsia
Timeframe: Change in metamorphopsia from baseline at 180 days.
Visual Acuity
Timeframe: Change in visual acuity from baseline at 180 days
Area of central scotoma
Timeframe: Change in area of central scotoma from baseline at 180 days
Central fovea thickness
Timeframe: Change in fovea thickness from baseline at 180 days